Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.
Stocks · News reference
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.
Immix Biopharma shares are trading lower. A report suggested that a fugitive worked as an executive for the company.